Intellia Therapeutics stock gains on CRISPR treatment results
Intellia Therapeutics Inc. (NTLA) shares gained 6.4% premarket on Monday after the clinical stage genome-editing company announced new data from a trial of an investigational CRISPR-based therapy for hereditary angioedema. Patients treated with a single dose of the therapy, NTLA-2002, saw durable elimination of their attacks, according to Intellia data shared Sunday at the European Academy of Allergy and Clinical Immunology conference in Hamburg, Germany. Hereditary angioedema is a rare genetic disorder that can cause severe inflammatory attacks in organs and tissues.
-Eleanor Laise
This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.
(END) Dow Jones Newswires
06-12-23 0800ET
Copyright (c) 2023 Dow Jones & Company, Inc.-
Magnificent 7 Stocks Earnings Updates: AI Remains the Focus
-
Small-Cap and Value Stocks Are Undervalued
-
Why We Expect the Job Market’s Slowdown to Renew in 2024
-
5 Undervalued Stocks to Buy to Play a Little Defense
-
Markets Brief: AI Leaders Excel In Earnings Season So Far
-
What History Tells Us About the Fed’s Next Move
-
What’s Happening In the Markets This Week
-
Alphabet’s New Dividend: What Investors Need to Know
-
Amazon Earnings: AWS Growth Accelerates and Profit Margins Improve
-
SiriusXM Earnings: Decent Results With Plan for Technology and Content Investment to Drive Growth
-
Coca-Cola Earnings: Solid Volume On Innovation and Digital Engagement
-
Is Berkshire Hathaway a Buy Before the Annual Meeting?
-
Investment Opportunities in the Drug Distribution Industry
-
Why the End of Quantitative Tightening Matters
-
Eli Lilly Earnings: Strong Weight-Loss Drug Sales Expand Margins
-
After Earnings, Is Meta Stock a Buy, a Sell, or Fairly Valued?